| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1016/J.TIPS.2016.10.014 |
| P8608 | Fatcat ID | release_lf2zdpgebngmliyvijg34a6jou |
| P698 | PubMed publication ID | 27916280 |
| P50 | author | Séverine Vermeire | Q30247983 |
| Ole Haagen Nielsen | Q37836698 | ||
| P2093 | author name string | Mehmet Coskun | |
| P433 | issue | 2 | |
| P921 | main subject | inflammation | Q101991 |
| inflammatory bowel diseases | Q917447 | ||
| P304 | page(s) | 127-142 | |
| P577 | publication date | 2016-12-01 | |
| P1433 | published in | Trends in Pharmacological Sciences | Q2451474 |
| P1476 | title | Novel Targeted Therapies for Inflammatory Bowel Disease | |
| P478 | volume | 38 |
| Q100491080 | A STAT3 palmitoylation cycle promotes TH17 differentiation and colitis |
| Q52364429 | A systems pharmacology model for inflammatory bowel disease. |
| Q47157018 | Ablation of ceramide synthase 2 exacerbates dextran sodium sulphate-induced colitis in mice due to increased intestinal permeability. |
| Q57111959 | Bile Acids Activated Receptors Regulate Innate Immunity |
| Q61818531 | Cardiovascular Manifestations of Inflammatory Bowel Disease: Pathogenesis, Diagnosis, and Preventive Strategies |
| Q47171488 | Clinical trials using mesenchymal stem cells in liver diseases and inflammatory bowel diseases |
| Q30356090 | Detection and characterization of murine colitis and carcinogenesis by molecularly targeted contrast-enhanced ultrasound |
| Q90233338 | Disruption of FOXP3-EZH2 Interaction Represents a Pathobiological Mechanism in Intestinal Inflammation |
| Q92003948 | Efficacy and safety of methotrexate in the management of inflammatory bowel disease: A systematic review and meta-analysis of randomized, controlled trials |
| Q58099968 | Emerging Therapies for Inflammatory Bowel Disease |
| Q91639033 | Fecal microbiota transplantation ameliorates active ulcerative colitis |
| Q47245673 | Fluorescence-mediated Tomography for the Detection and Quantification of Macrophage-related Murine Intestinal Inflammation |
| Q33852257 | Golimumab for the treatment of ulcerative colitis. |
| Q91636298 | Human Intestinal Mononuclear Phagocytes in Health and Inflammatory Bowel Disease |
| Q52602772 | Immunotherapy in inflammatory bowel disease: novel and emerging treatments. |
| Q55512056 | Improving IBD Care: A Personalized Approach to Management. |
| Q91521259 | Inflammatory Bowel Disease: A Stressed "Gut/Feeling" |
| Q89839206 | Inflammatory bowel disease: between genetics and microbiota |
| Q49570157 | Inflammatory bowel disease: towards a personalized medicine. |
| Q39388017 | Intestinal barrier integrity and inflammatory bowel disease: Stem cell-based approaches to regenerate the barrier. |
| Q33868659 | JNK Pathway-Associated Phosphatase/DUSP22 Suppresses CD4+ T-Cell Activation and Th1/Th17-Cell Differentiation and Negatively Correlates with Clinical Activity in Inflammatory Bowel Disease |
| Q55404573 | Mesenchymal stromal cells-derived matrix Gla protein contribute to the alleviation of experimental colitis. |
| Q42378152 | Metabonomics uncovers a reversible proatherogenic lipid profile during infliximab therapy of inflammatory bowel disease |
| Q90258770 | Novel Non-biologic Targets for Inflammatory Bowel Disease |
| Q50146115 | Novel Therapies and Treatment Strategies for Patients with Inflammatory Bowel Disease |
| Q47149665 | Protective Effect of Pogostone on 2,4,6-Trinitrobenzenesulfonic Acid-Induced Experimental Colitis via Inhibition of T Helper Cell |
| Q57156865 | Proteomics and Lipidomics in Inflammatory Bowel Disease Research: From Mechanistic Insights to Biomarker Identification |
| Q47103249 | Role of Incretin Axis in Inflammatory Bowel Disease. |
| Q91706575 | Serious and Opportunistic Infections in Elderly Patients With Inflammatory Bowel Disease |
| Q91809503 | Short and Long-Term Effectiveness of Ustekinumab in Patients with Crohn's Disease: Real-World Data from a German IBD Cohort |
| Q41050086 | Solid lipid nanoparticles delivering anti-inflammatory drugs to treat inflammatory bowel disease: Effects in an in vivo model |
| Q49316629 | Suppression Colitis and Colitis-Associated Colon Cancer by Anti-S100a9 Antibody in Mice |
| Q45740348 | Suppression of inflammation and tissue damage by a hookworm recombinant protein in experimental colitis |
| Q90726860 | TNFα inhibitors exacerbate Mycobacterium paratuberculosis infection in tissue culture: a rationale for poor response of patients with Crohn's disease to current approved therapy |
| Q38686563 | The alternate effects of anti-TNFα therapeutics and their role in mycobacterial granulomatous infection in Crohn's disease |
| Q38648792 | The potential of FimH as a novel therapeutic target for the treatment of Crohn's disease. |
| Q91948303 | The protective effect of syringic acid on dextran sulfate sodium-induced experimental colitis in BALB/c mice |
| Q94093743 | UEG Week 2018 Oral Presentations |
| Q47327588 | Updated treatment strategies for intestinal Behçet's disease |
| Q88990998 | [What rheumatologists can learn from gastroenterologists] |
Search more.